Toxic pulmonary effects of photodynamic therapy (PDT) in a mouse model

A major limitation of PDT for Barrett's esophagus is the development of esophageal strictures. This report summarizes the effects of PDT delivered to mouse esophagus. Sixty-two C3H/Nsd mice were injected with Photofrin (2-10mg/Kg) intraperitoneally. Forty-eight hours later a 1 cm laser probe was passed orally to the mid-esophagus. Light energy (630nm) ranged from 0 to 400 Joules/cm (J). Animals were sacrificed if death was imminent, otherwise at 6 weeks and 3 months. Gross and microscopic exams were performed on paraffin embedded esophagus and lung specimens. Exposure to 400J as a single fraction, 125 X 3 or 150 X 3 fractions resulted in a lethal pulmonary injury in 90% of mice within 48 hours. There was no esophageal mucosal damage at this early time point. Lower doses caused minor pulmonary injury allowing long-term survival but no change in the esophageal endothelium and no stricture. In the mouse, this histopathologic study demonstrates that pulmonary toxicity is the limiting factor following esophageal PDT. At lower PDT doses, minimal pulmonary damage occurred but no effect was observed on the esophagus. We believe the 5 mm depth of PDT injury leads to lethal pulmonary damage preventing subsequent study of the effects on the esophagus.

[1]  Kenneth K Wang,et al.  Photodynamic therapy in Barrett's esophagus. , 2003, Gastrointestinal endoscopy clinics of North America.

[2]  M. Epperly,et al.  Intratracheal injection of manganese superoxide dismutase (MnSOD) plasmid/liposomes protects normal lung but not orthotopic tumors from irradiation , 2000, Gene Therapy.

[3]  J. Luketich,et al.  Photodynamic therapy: results of curative intent for esophageal cancer and Barrett's with high-grade dysplasia in high-risk patients , 2000 .

[4]  P. Schauer,et al.  Minimally invasive esophagectomy for Barrett's esophagus with high-grade dysplasia. , 2000, Surgery.

[5]  M. Kibbe,et al.  Inducible nitric oxide synthase and vascular injury. , 1999, Cardiovascular research.

[6]  J. Greenberger,et al.  Manganese [correction of Magnesium] superoxide dismutase (MnSOD) plasmid/liposome pulmonary radioprotective gene therapy: modulation of irradiation-induced mRNA for IL-I, TNF-alpha, and TGF-beta correlates with delay of organizing alveolitis/fibrosis. , 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  B. Overholt.  Results of photodynamic therapy in Barrett's esophagus: A review. , 1999, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[8]  J. Luketich,et al.  Photodynamic therapy for treatment of malignant dysphagia. , 1999, Surgical laparoscopy, endoscopy & percutaneous techniques.

[9]  Kenneth K Wang,et al.  Current status of photodynamic therapy of Barrett's esophagus. , 1999, Gastrointestinal endoscopy.

[10]  N. Oleinick,et al.  The photobiology of photodynamic therapy: cellular targets and mechanisms. , 1998, Radiation research.

[11]  N. Shepherd,et al.  The histopathology of treated Barrett's esophagus: squamous reepithelialization after acid suppression and laser and photodynamic therapy. , 1998, The American journal of surgical pathology.

[12]  R. Sampliner,et al.  Ablative therapies for the columnar-lined esophagus. , 1997, Gastroenterology clinics of North America.

[13]  L. Karnell,et al.  National Cancer Data Base report on esophageal carcinoma , 1996, Cancer.

[14]  J. Luketich,et al.  Bronchoesophagopleural fistula after photodynamic therapy for malignant mesothelioma. , 1996, The Annals of thoracic surgery.

[15]  Yang Gr,et al.  Endoscopic Nd:YAG Laser Therapy in Patients with Early Superficial Carcinoma of the Esophagus and the Gastric Cardia , 1994, Endoscopy.

[16]  M. Endo.  Endoscopic Resection as Local Treatment of Mucosal Cancer of the Esophagus , 1993, Endoscopy.

[17]  J. Fraumeni,et al.  Continuing climb in rates of esophageal adenocarcinoma: an update. , 1993, JAMA.

[18]  W. Samowitz,et al.  Restoration of squamous mucosa after ablation of Barrett's esophageal epithelium. , 1993, Gastroenterology.

[19]  A R Zinsmeister,et al.  Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. , 1993, Gastroenterology.

[20]  Shigeru Suzuki,et al.  Endoscopic Photodynamic Therapy for Esophageal Cancer , 1989 .

[21]  J. Blankensteijn,et al.  Adenocarcinoma in Barrett's oesophagus: an overrated risk. , 1989, Gut.

[22]  L. Oberley,et al.  The apparent production of superoxide and hydroxyl radicals by hematoporphyrin and light as seen by spin‐trapping , 1980, FEBS letters.

[23]  J. Greenberger,et al.  Overexpression of the human manganese superoxide dismutase (MnSOD) transgene in subclones of murine hematopoietic progenitor cell line 32D cl 3 decreases irradiation-induced apoptosis but does not alter G2/M or G1/S phase cell cycle arrest. , 1999, Radiation oncology investigations.

[24]  C. Lightdale.  Ablation therapy for Barrett's esophagus: is it time to choose our weapons? , 1999, Gastrointestinal endoscopy.

[25]  B. Overholt,et al.  Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. , 1999, Gastrointestinal endoscopy.

[26]  J. Greenberger,et al.  Prevention of irradiation-induced esophagitis by plasmid/liposome delivery of the human manganese superoxide dismutase transgene. , 1999, Radiation oncology investigations.

[27]  W. Blot.  Esophageal cancer trends and risk factors. , 1994, Seminars in oncology.